Journal article · 2023 · Open access
Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data
Epidemiology and Health, 45, e2023045 · Published 15 April 2023 · DOI 10.4178/epih.e2023045
In brief
“Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data” is a 2023 journal article by Hong Ki Min and 8 co-authors, published in Epidemiology and Health. OpenAlex counts 27 citations as of 19 November 2026, which puts it in the top 5% of works published in 2023 by citations. It is open access under a CC BY licence: the full text is free to read at Epidemiology and Health.
- Citations
- 27
- Most cited in
- 2025 (13)
- Field-weighted impact
- 4.50
- References
- 40
- Authors
- 9
Abstract
OBJECTIVES: This study investigated whether Janus kinase inhibitors (JAKis) raise the risk of cardiovascular disease (CVD), venous thromboembolism (VTE), and cancer in patients with rheumatoid arthritis (RA). METHODS: We conducted a real-world retrospective observational study using data obtained from the Korean National Health Insurance Service database. Two data sets were analyzed: tumor necrosis factor inhibitor (TNFi)/JAKi-naive RA patients (set 1) and all RA patients who used TNFis or JAKis (set 2). The incidence rate ratios (IRRs) and hazard ratios (HRs) for acute myocardial infarction (AMI), stroke, cardiovascular (CV)-related mortality, major adverse cardiovascular events (MACE), VTE, arterial thromboembolism (ATE), cancer, and all-cause mortality were compared between the JAKi and TNFi groups. RESULTS: Set 1 included 1,596 RA patients (JAKi group: 645; TNFi group: 951), and set 2 included 11,765 RA patients (JAKi group: 2,498; TNFi group: 9,267). No adverse events (AEs) showed significantly higher IRRs in the JAKi groups than in the TNFi groups of sets 1 and 2. The HRs for MACE in the JAKi groups of sets 1 and 2 were 0.59 (95% confidence [CI], 0.35 to 0.99) and 0.80 (95% CI, 0.67 to 0.97), respectively. The JAKi group of set 2 showed a significantly higher risk of all-cause mortality (HR, 1.71; 95% CI, 1.32 to 2.20), but the other AEs did not demonstrate increased risks in the JAKi groups. CONCLUSIONS: In this study, JAKis did not increase the risk of AMI, stroke, CV-related mortality, MACE, VTE, ATE, or cancer in Korean RA patients relative to TNFis.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Min, H. K., Kim, H., Jeong, H. J., Kim, H., Kim, H.-R., Park, J. H., Lee, K.-S., Shin, S., & Park, J. H. (2023). Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data. Epidemiology and Health, 45, e2023045. https://doi.org/10.4178/epih.e2023045
MLA 9
Min, Hong Ki, et al. “Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.” Epidemiology and Health, vol. 45, 2023, p. e2023045. https://doi.org/10.4178/epih.e2023045.
Chicago
Min, Hong Ki, Hyeongsu Kim, Ho Jin Jeong, Hae‐Rim Kim, Hae-Rim Kim, Jong Heon Park, Kun-Sei Lee, Soon‐Ae Shin, and Jong Heon Park. 2023. “Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data.” Epidemiology and Health 45: e2023045. https://doi.org/10.4178/epih.e2023045.
Harvard
Min, H. K. et al. (2023) ‘Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data’, Epidemiology and Health, 45, p. e2023045. doi:10.4178/epih.e2023045.
IEEE
H. K. Min et al., “Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data,” Epidemiology and Health, vol. 45, p. e2023045, 2023, doi: 10.4178/epih.e2023045.
BibTeX
@article{min2023risk,
title = {{Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data}},
author = {Min, Hong Ki and Kim, Hyeongsu and Jeong, Ho Jin and Kim, Hae‐Rim and Kim, Hae-Rim and Park, Jong Heon and Lee, Kun-Sei and Shin, Soon‐Ae and Park, Jong Heon},
journal = {Epidemiology and Health},
year = {2023},
volume = {45},
pages = {e2023045},
doi = {10.4178/epih.e2023045},
url = {https://doi.org/10.4178/epih.e2023045}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2023 | 3 | |
| 2024 | 4 | |
| 2025 | 13 | |
| 2026 | 7 |
Its field-weighted citation impact is 4.50: it has been cited 4.50 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- tumor necrosis factor inhibitors
- cardiovascular disease
- venous thromboembolism
- arterial thromboembolism
- cancer risk
- mortality
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Min, H. K., Kim, H., Jeong, H. J., Kim, H., Kim, H.-R., Park, J. H., Lee, K.-S., Shin, S., & Park, J. H. (2023). Risk of cancer, cardiovascular disease, thromboembolism, and mortality in patients with rheumatoid arthritis receiving Janus kinase inhibitors: a real-world retrospective observational study using Korean health insurance data. Epidemiology and Health, 45, e2023045. https://doi.org/10.4178/epih.e2023045
How many times has this paper been cited?
27 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Epidemiology and Health: sign in and open the PDF from this page.
Who wrote this paper?
Hong Ki Min, Hyeongsu Kim, Ho Jin Jeong, Hae‐Rim Kim, Hae-Rim Kim, Jong Heon Park, Kun-Sei Lee, Soon‐Ae Shin, Jong Heon Park.
What is the DOI of this paper?
10.4178/epih.e2023045, permanently at https://doi.org/10.4178/epih.e2023045. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.